HMGB2 and hepatocellular carcinoma: Based on the HCC bulk RNA-seq data analysis in the BEST platform, it was observed that in the TCGA-LIHC cohort, the subgroup with high HMGB2 expression had poorer OS (Figure 6A), PFS (Figure 6B), DFS (Figure 6C), and DSS (Figure 6D) than the low-expression group.